LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Challenging Issues in the Management of Chronic Hepatitis B Virus, An Issue of Clinics in Liver Disease
- 1st Edition, Volume 25-4 - September 29, 2021
- Editor: Mitchell L Shiffman
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 8 1 0 6 8 - 5
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 1 0 6 9 - 2
In this issue of Clinics in Liver Disease, guest editor Mitchell L Shiffman brings considerable expertise to the topic of Challenging Issues in the Management of Chronic Hepa… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Clinics in Liver Disease, guest editor Mitchell L Shiffman brings considerable expertise to the topic of Challenging Issues in the Management of Chronic Hepatitis B Virus.
- Provides in-depth, clinical reviews on the latest updates in Challenging Issues in the Management of Chronic Hepatitis B Virus, providing actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- The Changing Demographics of Hepatitis B Virus Infection
- Key points
- Introduction
- Impact of recent immigration from Asia, Middle East, Africa and Central America to Europe, North America/USA, and Australia
- The impact of vaccination on the incidence and prevalence of hepatitis B virus infection
- Perspectives
- Clinics care points
- Interpretation of HBV Serologies
- Key points
- History of serologic testing. The Australia antigen
- Review serologic tests used to detect HBV
- Role of surface antigen
- Role of HBV DNA testing
- Role of HBV genotypes
- Relationship of serology and HBV DNA to disease progression
- Monitoring acute and chronic HBV with serologic testing
- Mutations of HBV and how this may confuse serologic interpretation
- Clinics care points
- Disclosure
- Treatment and Prevention of Acute Hepatitis B Virus
- Key points
- Incidence of acute hepatitis B virus
- Clinical course
- Preventing acute hepatitis B virus in adults
- Preventing acute hepatitis B virus in newborns
- Fulminant liver failure from acute hepatitis B virus
- Indications for oral antiviral agents in acute hepatitis B virus
- Is there harm in using antiviral therapy in early hepatitis B virus infection?
- Summary
- Clinics care points
- Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy
- Key points
- Indications for antiviral therapy
- Role of Hepatitis B HBV DNA as the indication for antiviral therapy
- Role of e antigen status in therapy
- Results of oral antiviral therapy: a comparison of efficacy and side effects
- What to do when oral antiviral therapy fails to decrease hepatitis B DNA to undetectable: Is there a role for combination therapy?
- Switching to tenofovir disoproxil fumarate versus combination therapy
- Switching to tenofovir alafenamide
- Summary
- Clinics care points
- Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa
- Key points
- Introduction
- Interferon and pegylated interferon for the treatment of chronic hepatitis B virus
- E-antigen and S-antigen seroconversion with pegylated interferon versus oral antiviral therapy
- Role of S-antigen titer in monitoring pegylated interferon treatment
- Combining pegylated interferon and oral antiviral therapy
- Patients who are the best candidates for pegylated interferon therapy consideration
- Clinics care points
- Disclosure
- Controversies in Treating Chronic Hepatitis B virus: The Role of Hepatitis B Virus DNA and Surface Antigen Titer
- Key points
- Introduction
- Should patients with high hepatitis B virus DNA levels but normal alanine aminotransferase levels be treated to prevent hepatocellular carcinoma?
- Should patients with high hepatitis B virus DNA levels but normal alanine aminotransferase levels be treated to prevent reactivation and cirrhosis?
- Can quantitative hepatitis B surface antigen and hepatitis B virus DNA help to identify which patients will remain inactive?
- Can quantitative hepatitis B surface antigen be used to determine when to stop treatment?
- Are baseline factors or on-treatment factors better to predict hepatitis B surface antigen seroclearance in patients?
- Summary
- Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma
- Key points
- Introduction
- Risk factors for hepatocellular carcinoma in hepatitis B infection
- Incident risk of hepatocellular carcinoma in untreated hepatitis B
- Impact of antiviral therapy on incident risk of hepatocellular carcinoma
- Role of predictive risk scores for hepatocellular carcinoma in chronic hepatitis B
- Should children with immune-tolerant disease be screened for hepatocellular carcinoma and at what interval
- Target pediatric hepatitis B virus population for hepatocellular carcinoma surveillance
- Tools used to screen for hepatocellular carcinoma in hepatitis B virus subjects
- Should histologic severity affect the frequency of hepatocellular carcinoma screening
- Factors influencing the frequency of hepatocellular carcinoma surveillance
- Treatment of hepatitis B virus in patients who develop hepatocellular carcinoma not on hepatitis B virus therapy
- Choice of nucleoside analogue therapy in managing hepatitis B virus–related hepatocellular carcinoma
- Treatment of hepatitis B virus in patients who develop hepatocellular carcinoma while on anti–hepatitis B virus therapy
- Summary
- Clinics care points
- Disclosures
- Controversies in Treating Chronic Hepatitis B Virus Infection: Discordant Serologic Results
- Key points
- Introduction
- Identifying chronic hepatitis B virus when serologic results are discordant
- Summary
- Clinics care points
- Chronic Hepatitis B Virus in Patients with Chronic Hepatitis C Virus
- Key points
- Epidemiology of hepatitis B virus, hepatitis C virus, and coinfection
- Interaction of hepatitis viruses
- Treatment of hepatitis B virus and hepatitis C virus
- Treatment of patients with hepatitis B virus–hepatitis C virus coinfection
- Summary
- New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection
- Key points
- Introduction
- Epidemiology and natural history of hepatitis D virus infection
- Virology of hepatitis B virus/hepatitis D virus coinfection and serologic and virologic testing for hepatitis D virus
- Interferon-based treatment of chronic hepatitis D virus infection
- Novel treatments against hepatitis D virus infection
- Clinics care points
- Use of Hepatitis B Virus–Positive Organs in Organ Transplantation
- Key points
- Historical perspective
- Hepatitis B testing of organ donors
- Natural history and outcomes with use of anti–hepatitis B core antigen–positive, hepatitis B surface antigen–negative donors
- Recommendations for use of anti-hepatitis B core antigen–positive, hepatitis B surface antigen–negative organs
- Natural history and outcomes with the use of hepatitis B surface antigen–positive donors
- Recommendations for use of hepatitis B surface antigen–positive organs
- Can antiviral prophylaxis for hepatitis B virus after liver transplantation ever be stopped?
- Vaccination in transplant candidates and recipients
- Clinics care points
- Disclosure
- Hepatitis B and Health Care Workers
- Key points
- The risk of transmission of hepatitis B virus to health care workers: background and historical perpsectives
- Vaccination of health care workers
- The need for booster therapy
- Hepatitis B virus vaccination failure in health care workers
- Should hepatitis B virus screening and vaccination be mandatory for health care workers?
- Health care workers with chronic hepatitis B virus
- Summary
- Clinics care points
- Novel Therapies That May Cure Chronic Hepatitis B Virus
- Key points
- The hepatitis B virus
- cccDNA and why it is so hard to eradicate
- Endpoints of therapy and targeted populations
- Proposed strategies for novel hepatitis B virus therapies
- Drugs in development (phase I studies)
- Summary
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 25-4
- Published: September 29, 2021
- Imprint: Elsevier
- Hardback ISBN: 9780323810685
- eBook ISBN: 9780323810692
MS
Mitchell L Shiffman
Affiliations and expertise
Director, Bon Secours Liver Institute of Richmond, Bon Secours Liver Instiutute of Hampton, St Mary’s Hospital, Richmond, VA, USA